Detail akcie Royal Pharm Rg -A online

Business Summary: Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Royalty Pharma plc revenues increased 4% to $1.15B. Net income increased from $106.8M to $268.5M. Revenues reflect Financial Royalty Assets increase of 3% to $1.09B, Royalty Income Other increase of 12% to $57M. Net income benefited from Provision for changes in expected cash f decrease from $796M (expense) to $331.1M (income).